Search results
A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings. Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
- Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G. Ross, Mohammad Sharif Hossain, John D. Clemens, Mar...
- 2021
- Recommendation
- Rationale
- References
The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
The Panel’s recommendation is primarily informed by adequately powered, randomized trials of ivermectin that reported clinical outcomes. Studies that randomized participants to receive ivermectin or a matched placebo had the greatest impact on the Panel’s recommendation.6-13
Trials have failed to find a clinical benefit of using ivermectin to treat COVID-19 in outpatients. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%).14 In addition, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%). In COVID-OUT, a randomized factorial trial, the use of ivermectin did not reduce the occurrence of a composite outcome of emergency department visits, hospitalization, or death when compared with a matched control (5.7% vs. 4.1%).6
Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445-455. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25130507.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26954318.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32251768.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32314704.
Mar 30, 2022 · To evaluate the efficacy of ivermectin for the prevention of progression of Covid-19 resulting in hospitalization among outpatients with SARS-CoV-2 infection, we conducted a randomized,...
Apr 5, 2024 · Here’s What You Need to Know. The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals. The FDA has determined that currently...
It is best to take this medicine on an empty stomach. Swallow the tablet with water. To help clear up your infection, take this medicine exactly as directed. Your doctor may want you to take another dose every 3 to 12 months. Dosing . The dose of this medicine will be different for different patients.
Jun 21, 2021 · The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit. Our certainty of evidence judgment was consolidated by the results of trial sequential analyses, which show that the required IS has probably already been met.
Jul 29, 2022 · Ivermectin should only be used in patients for COVID-19 treatment in a research setting, as part of a clinical trial. Ivermectin products that are approved for use in animals should NOT be taken by humans.
